Risk of Hemolytic Disease of the Newborn (HDN) when an Rh-negative Mother Carries an Rh-positive Fetus

Click for Info
Fertility Booster
Antihyperglycemic Drug
Antihyperglycemic Drug
Antihyperglycemic Drug
Fertility Boost
Pregnancy Support
Online Pharmacy Medcoi.com

Risk of Hemolytic Disease of the Newborn (HDN) when an Rh-negative mother carries an Rh-positive fetus

When an Rh-negative mother carries an Rh-positive fetus, there is a risk of hemolytic disease of the newborn (HDN) because the mother’s immune system may produce antibodies against the Rh antigen in the fetal blood, leading to the destruction of fetal red blood cells. This condition can lead to jaundice, anemia, and other complications in the newborn.

In recent years, mortality rates related to HDN have significantly decreased due to the widespread use of Rh immunoglobulin (RhIg) prophylaxis during pregnancy. RhIg is a medication given to Rh-negative mothers to prevent the formation of Rh antibodies and thus reduce the risk of HDN.

When an Rh-positive mother carries an Rh-negative fetus, there is usually no risk of HDN, as the mother’s immune system does not typically produce antibodies against Rh-negative blood. However, in rare cases, if the mother has been previously sensitized to the Rh antigen (e.g., through a previous pregnancy or blood transfusion), she may develop antibodies that can cross the placenta and cause HDN in the fetus.

The management of HDN has also improved in recent years with advances in neonatal medicine and the availability of intrauterine transfusions, which can be used to treat severe cases of the disease before birth.

Overall, while there is still a risk of HDN in Rh-incompatible pregnancies, the use of RhIg prophylaxis and improvements in management have led to a significant reduction in mortality rates in recent years.

RhIG, also known as Rh immune globulin or anti-D immunoglobulin, is administered during pregnancy and postpartum under specific circumstances to prevent Rh isoimmunization, a condition that can lead to hemolytic disease of the newborn (HDN) in subsequent pregnancies. RhIG is typically recommended at 26 to 28 weeks gestation and postpartum if the newborn is Rh positive.

During pregnancy, RhIG is administered to Rh-negative women who are at risk of sensitization to Rh-positive fetal blood cells. Sensitization occurs when fetal Rh-positive red blood cells enter the maternal circulation, triggering an immune response in Rh-negative individuals. RhIG works by binding to and neutralizing Rh-positive fetal cells, preventing the maternal immune system from mounting an alloimmune response against them.

The administration of RhIG at 26 to 28 weeks gestation serves as a prophylactic measure to mitigate the risk of Rh sensitization during the latter stages of pregnancy, particularly during episodes of fetomaternal hemorrhage, which can occur during routine prenatal procedures or spontaneously.

Additionally, RhIG is recommended postpartum if the newborn is Rh positive to prevent sensitization events that may have occurred during childbirth. Even if the newborn’s blood type is not definitively known at birth, RhIG administration is indicated as a precautionary measure, given the potential risk of maternal sensitization to Rh-positive fetal cells.

The rationale behind administering RhIG in these specific situations is to prevent the development of Rh isoimmunization in Rh-negative women, thereby reducing the risk of HDN in subsequent pregnancies. HDN occurs when maternal antibodies against fetal red blood cells cross the placenta, leading to hemolysis and subsequent fetal anemia, jaundice, and, in severe cases, fetal hydrops and intrauterine demise.

By providing passive immunity against Rh-positive fetal cells, RhIG effectively suppresses the maternal immune response to Rh antigen exposure, thereby safeguarding the health and well-being of both current and future pregnancies. The timely administration of RhIG according to established guidelines is a crucial aspect of antenatal and postpartum care for Rh-negative women, ensuring optimal outcomes for mother and baby alike

What to do if the blood group compatibilty test is unmatched


Verified by: Dr.Diab (March 29, 2024)

Citation: Dr.Diab. (March 29, 2024). Risk of Hemolytic Disease of the Newborn (HDN) when an Rh-negative Mother Carries an Rh-positive Fetus. Medcoi Journal of Medicine, 7(2). urn:medcoi:article21391.

There are no comments yet

× You need to log in to enter the discussion
© 2024 Medcoi LLC, all rights reserved.
go to top